RESUMEN
OBJECTIVE: Our purpose was to determine whether the bone resorption rate is evaluated by Deoxypyridinoline(Dpd) i urine, and to evaluate the clinical utility of Dpd to monitor the hormone replacement therapy effect in postmenopausal women. STUDY DESIGN: We divided the patients into three groups, the control group was the women who were postmenopausal health state, and the experimental groups were the postmenopausal hormone replacement therapy group and the podtmenopausal nontherapy group. Urinary Dpd and serum FSH, Osteocalcin was measured in the both groups. RESULTS: The urinary Dpd and serum osteocalcin were significantly increase in postmenopausal group(6.63+/-3.09 pmol/nmol creatinine; 10.54+/-3.77 ng/ml) compared to premenopausal group(4.15+/-1.32 pmol/nmol creatinine; 7.85+/-2.17 ng/ml). The urinary Dpd and Serum osteocalcin were significantly decreased in the postmenopausal HRT group(3.31+/-1.79 pmol/nmol creatinine; 8.31+/-3.13 ng/ml) compared to the postmenopausal nontherapy group (6.63+/-3.09 pmol/nmol creatinine; 10.54+/-3.77 ng/ml). In postmenopausal nontherapy group, there was no correlation between urinary Dpd and serum osteocalcin. But these makers were good correlated in postmenopausal HRT group. CONCLUSIONS: It is concluded that the assay of urinary Dpd is useful for the resorption marker of postmenopausal osteoporosis and it should be useful for the monitoring of hormone replacement therapy effect in postmenopausal women. Furthermore, urinary Dpd may be an important indicator to determine when to resume the therapy during cessation of HRT.